Interactive revolution in eye care

Swiss Advanced Vision (SAV-IOL) is a Swiss manufacturer of high quality innovative intraocular lenses (IOLs) designed for cataract surgery. The company recently announced the start of a project for developing a revolutionary active intraocular lens, R-TASC (Real-Time Autofocus Servo Control), featuring real-time autofocus and wireless connectivity. Max Boysset, SAV-IOL CEO, believes R-TASC could disrupt the global IOL market and considerably improve the quality of life of millions of cataract patients around the world. He is looking to raise 20M CHF, over five years, to bring R-TASC to market. "This is an opportunity to totally transform patients' vision after cataract surgery and beyond."



Intraocular lenses (IOLs) are medical devices that are implanted inside the eye to replace the eye's natural lens when it is removed during cataract surgery. FDA-approved IOLs have been available since the early 1980s, but Mr. Boysset emphasises that while the global market for intraocular lenses is massive (projected to reach 4.56 billion USD by 2022 from estimated 3.50 billion in 2017), there has been little innovation since they were first introduced. "There is a level of compromise and trade-offs with all IOLs currently on the market."

R-TASC addresses the issues commonly associated with IOLs through an entirely novel approach. While all current lenses are passive (fixed design that should fit at the best for different people and life situations) they inevitably suffer from optical compromises, such as light distribution, resolution, and visual disturbances. The purpose of R-TASC is to fully restore the accommodative function normally provided by the crystalline lens of the eye. Based on an energy capture system, the R-TASC lens will focus on any object viewed by the patient, in real-time. Thanks to its open technology, the platform is also future proofed to incorporate augmented reality and other interactive or connected features. R-TASC will be fitted alongside a monofocal lens (for distant vision) or added on patients who already have a monofocal lens but want to restore their visual accommodation.

SAV-IOL has to date filed eight patents for innovative IOLs including R-TASC and is currently speaking to investors. " We are especially looking for investors who are truly fascinated by the technology," emphasises Mr. Boysset. The funds raised will be used to help form a technology consortium, needed because the development of R-TASC requires areas of expertise beyond conventional eye health, and to go through clinical trials, as well as, subsequently, the regulatory process. "It is vital to prove that R-TASC not only works, but also is 100% safe," says Mr. Boysset.

Further down the line, SAV-IOL's growing distribution network will be a good starting point for the commercialisation of R-TASC. The Swiss-based company currently sells EDOF IOLs (Extended Depth of Focus) into more than 40 countries worldwide.

SWISS ADVANCED VISION
INTRAOCULAR LENS

SAV-IOL SA
Website: www.sav-iol.com